Elicio Therapeutics, Inc. Common Stock
$1.77
-$0.22 (-11.06%)
$1.71Day Range$1.90
Key Statistics
Market Cap
$46.52M
Shares Outstanding
26.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 2, 2023
Round Lot
100
Locale
US
Trading Data
Day Open
$1.90
Day High
$1.90
Day Low
$1.71
Volume
629.9K
VWAP
$1.83
Prev Close
$1.99
Transactions
--
Acc. Volume
--
About Elicio Therapeutics, Inc. Common Stock
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
PHARMACEUTICAL PREPARATIONSSIC 283433 employees451 D STREET, 5TH FLOOR, BOSTON, MA, 02210(857) 209-0050IPO Jun 2, 2023US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001601485
- Composite FIGI
- BBG00444GM02
- Share Class FIGI
- BBG00444GM11
- Ticker Root
- ELTX
- SIC Code
- 2834
About Elicio Therapeutics, Inc. Common Stock (ELTX) Stock
Elicio Therapeutics, Inc. Common Stock (ELTX) closed the 2026-09-16 session at $1.77, down 11.06% versus the previous close (-0.22). The stock opened at $1.90 and traded between $1.71 and $1.90 during that session. Session trading volume was 630K shares. The volume-weighted average price (VWAP) is $1.83.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Elicio Therapeutics, Inc. Common Stock has a market capitalization of $46.5 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ELTX is listed on the XNAS exchange. The company employs approximately 33 people. Elicio Therapeutics, Inc. Common Stock is headquartered in BOSTON, MA. The recorded listing date is 2023-06-02.
On this page you can find market ELTX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.